{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:14:48Z","timestamp":1761178488915,"version":"build-2065373602"},"reference-count":21,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer\/Radioth\u00e9rapie"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.canrad.2018.07.010","type":"journal-article","created":{"date-parts":[[2018,8,6]],"date-time":"2018-08-06T18:42:40Z","timestamp":1533580960000},"page":"401-403","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Radioth\u00e9rapie \u00ab\u00a0involved node\u00a0\u00bb et \u00ab\u00a0involved site\u00a0\u00bb des lymphomes hodgkiniens\u00a0: quels volumes cible\u00a0?"],"prefix":"10.1016","volume":"22","author":[{"given":"K.","family":"Peignaux","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Gonzague-Casabianca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canrad.2018.07.010_bib0110","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1182\/asheducation-2016.1.323","article-title":"Long-term risk of second malignancy and cardiovascular disease after Hodgkin lymphoma treatment","volume":"2016","author":"Van Leeuwen","year":"2016","journal-title":"Am Soc Hematol Educ Program"},{"key":"10.1016\/j.canrad.2018.07.010_bib0115","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1200\/JCO.2011.38.8835","article-title":"Breast cancer risk after supradiaphragmatic radiotherapy for Hodgkin's lymphoma in England and Wales: a National Cohort Study","volume":"30","author":"Swerdlow","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2018.07.010_bib0120","first-page":"1007","article-title":"Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk","volume":"175","author":"Van Nimwegen","year":"2015","journal-title":"Intern Med"},{"key":"10.1016\/j.canrad.2018.07.010_bib0125","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1200\/JCO.2015.63.4444","article-title":"Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma","volume":"34","author":"Van Nimwegen","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2018.07.010_bib0130","first-page":"107","article-title":"Risk of valvular heart disease after treatment for Hodgkin lymphoma","author":"Cutter","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.canrad.2018.07.010_bib0135","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.clon.2004.07.004","article-title":"Long-term results of a randomised trial of involved field radiotherapy vs extended field radiotherapy in stage I and II Hodgkin lymphoma","volume":"17","author":"Hoskin","year":"2005","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.canrad.2018.07.010_bib0140","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ejca.2017.05.005","volume":"81","author":"Ferm\u00e9","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.canrad.2018.07.010_bib0145","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/annonc\/13.S1.79","article-title":"The involved field is back: issues in delineation the radiation field in Hodgkin's disease","volume":"13","author":"Yahalom","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.canrad.2018.07.010_bib0150","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","article-title":"Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC\/LYSA\/FIL H10\u00a0trial","volume":"35","author":"Andr\u00e9","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2018.07.010_bib0155","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.ijrobp.2012.08.041","article-title":"Involved node radiation therapy: an effective alternative in early-stage hodgkin lymphoma","volume":"85","author":"Maraldo","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2018.07.010_bib0160","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.ijrobp.2013.05.005","article-title":"Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the International Lymphoma Radiation Oncology Group (ILROG)","volume":"89","author":"Specht","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2018.07.010_bib0165","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.radonc.2006.05.015","article-title":"Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines","volume":"79","author":"Girinsky","year":"2006","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2018.07.010_bib0170","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.clon.2012.07.011","article-title":"Recommandations for the use of radiotherapy in nodal lymphoma","volume":"25","author":"Hoskin","year":"2013","journal-title":"Clin Oncol"},{"key":"10.1016\/j.canrad.2018.07.010_bib0175","doi-asserted-by":"crossref","first-page":"S244","DOI":"10.1016\/j.canrad.2016.07.012","article-title":"Radioth\u00e9rapie des lymphomes","volume":"20","author":"Barillot","year":"2016","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2018.07.010_bib0180","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.ijrobp.2014.04.026","article-title":"Role of FDG-PET in the implementation of involved-node radiation therapy for Hodgkin lymphoma patients","volume":"89","author":"Girinsky","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2018.07.010_bib0185","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.radonc.2008.05.012","article-title":"The conundrum of Hodgkin lymphoma nodes: to be or not to be included in the involved node radiation fields. The EORTC-GELA lymphoma group guidelines","volume":"88","author":"Girinsky","year":"2008","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2018.07.010_bib0190","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1007\/s00066-008-1882-7","article-title":"Involved-node radiotherapy in early-stage Hodgkin's lymphoma. Definition and guidelines of the German Hodgkin Study Group (GHSG)","volume":"184","author":"Eich","year":"2008","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.canrad.2018.07.010_bib0195","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0360-3016(01)01798-9","article-title":"Response-adapted radiotherapy in the treatment of pediatric Hodgkin's disease: an interim report at 5\u00a0years of the German GPOH-HD 95\u00a0trial","volume":"51","author":"R\u00fchl","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2018.07.010_bib0200","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ijrobp.2015.02.008","article-title":"Expert radiation oncologist interpretations of involved-site radiation therapy guidelines in the management of Hodgkin lymphoma","volume":"92","author":"Hoppe","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2018.07.010_bib0205","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s10147-015-0863-y","article-title":"The concept and evolution of \u00ab\u00a0involved site\u00a0\u00bb radiation therapy for lymphoma","volume":"20","author":"Specht","year":"2015","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.canrad.2018.07.010_bib0105","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.prro.2014.05.003","article-title":"International Lymphoma Radiation Oncology Group. Implementation of contemporary radiation therapy planning concepts for pediatric Hodgkin lymphoma. Guidelines from the International Lymphoma Radiation Oncology Group","volume":"5","author":"Hodgson","year":"2014","journal-title":"Pract Radiat Oncol"}],"container-title":["Cancer\/Radioth\u00e9rapie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321818301379?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321818301379?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T12:28:04Z","timestamp":1761136084000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1278321818301379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S1278321818301379"],"URL":"https:\/\/doi.org\/10.1016\/j.canrad.2018.07.010","relation":{},"ISSN":["1278-3218"],"issn-type":[{"type":"print","value":"1278-3218"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radioth\u00e9rapie \u00ab\u00a0involved node\u00a0\u00bb et \u00ab\u00a0involved site\u00a0\u00bb des lymphomes hodgkiniens\u00a0: quels volumes cible\u00a0?","name":"articletitle","label":"Article Title"},{"value":"Cancer\/Radioth\u00e9rapie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canrad.2018.07.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}